FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
Patients with resectable adenocarcinoma of the stomach or the esophagogastric junction
(II-III type by Siewert) without previous therapy will be treated with one of two
chemotherapy combinations before and after surgery. One half of the patients gets
5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Docetaxel (FLOT), the others
5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Irinotecan (FOLFIRINOX). Main objective of
the study is median overall survival.